Bayer's Stock Stays Glued to the 200-Day Line as Legal Storm Clouds Gather

Bayer shares trade at €35.81, just above the 200-day MA, as glyphosate settlement opt-out closes and Supreme Court preemption case looms. Technical and legal pressures converge.

Bayer shares are clinging to a technical lifeline at a moment when the legal calendar is intensifying. The stock traded at €35.81 on Friday, within a whisker of its 200-day moving average of €35.80, while the clock ticks on two critical US legal events: the opt-out period for a potential $7.25 billion glyphosate settlement has just closed, and the Supreme Court is expected to rule on a landmark preemption case by the end of June.

The proximity to the 200-day line is a flashpoint for traders. A decisive move above it would signal that the recent recovery has legs, while failure to hold could trigger another leg lower. That tension is playing out against a backdrop of elevated volatility — the 30-day annualised figure stands at 36.78% — and a 14-day relative strength index of 41.8, which keeps the stock in neutral territory, not yet oversold enough to guarantee a technical bounce.

Chart Levels Tell a Story of Decay

Beneath the surface, the technical picture is more fragmented. The 50-day moving average sits at €38.39, a full 6.72% above the current price, while the 100-day average at €40.50 is even further out of reach. That gap underscores how far the stock has fallen from its short-term momentum. Over the past month, Bayer has shed 7.04%, and on a weekly basis it is down 1.84%. The year-to-date deficit now stands at 5.83%.

Yet the longer view tempers some of the gloom. Over the past twelve months, Bayer still trades 36.24% higher, and the distance from its 52-week low of €25.09 — set on 6 August 2025 — is a hefty 42.70%. The problem is the distance from the high. The stock peaked at €49.93 on 17 February 2026, meaning it has since surrendered 28.28% of that peak. The recovery from last summer’s trough has stalled well short of the old highs.

The Legal Overhang Comes into Focus

Technical analysis alone cannot explain Bayer’s recent weakness; the legal front is just as decisive. The opt-out deadline for the proposed $7.25 billion settlement covering more than 60,000 plaintiffs passed on Thursday. The company had been pushing for nearly 100% participation to cap its exposure. With that window now closed, the viability of the settlement will become clearer in the coming weeks.

Running in parallel is the “Durnell” case, now before the US Supreme Court. At issue is whether a company can be held liable under state law for a product that the Environmental Protection Agency has deemed safe. Bayer has acknowledged that it does not necessarily expect a victory, yet the mere acceptance of the case by the high court is seen as a step toward containing the litigation. A decision is due before the current term ends in June.

CEO Bill Anderson has been candid about the risks, even as the company pushes ahead with cost-cutting and digital initiatives in its pharma and chemicals divisions. Those operational improvements are largely overshadowed by the legal uncertainty, and as long as the Supreme Court ruling and settlement participation remain unresolved, the stock is likely to remain at the mercy of news flow.

Key Levels to Watch

For now, the technical floor is the 200-day line, but the next meaningful support lies at €33.60. To the upside, a reclaim of €38.10 would brighten the outlook, with €41.77 as the next target. Given the mix of chart resistance and legal ambiguity, Bayer shares look set for sharp, news-driven swings until the current legal milestones are passed.